Page last updated: 2024-09-04

cyc 202 and at 7519

cyc 202 has been researched along with at 7519 in 8 studies

Compound Research Comparison

Studies
(cyc 202)
Trials
(cyc 202)
Recent Studies (post-2010)
(cyc 202)
Studies
(at 7519)
Trials
(at 7519)
Recent Studies (post-2010) (at 7519)
979739327024

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)at 7519 (IC50)
Cyclin-T1Homo sapiens (human)0.0093
Cyclin-dependent kinase 14Homo sapiens (human)0.0198
Cyclin-dependent kinase 1Homo sapiens (human)0.1729
Cyclin-dependent kinase 4Homo sapiens (human)0.0939
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.1682
Cyclin-A2Homo sapiens (human)0.063
G1/S-specific cyclin-D1Homo sapiens (human)0.1168
G1/S-specific cyclin-E1Homo sapiens (human)0.36
Cyclin-dependent kinase 2Homo sapiens (human)0.0586
G1/S-specific cyclin-D3Homo sapiens (human)0.153
Glycogen synthase kinase-3 betaHomo sapiens (human)0.2
Cyclin-dependent kinase 7Homo sapiens (human)2.4
Cyclin-dependent kinase 9Homo sapiens (human)0.0094
Cyclin-HHomo sapiens (human)2.4
CDK-activating kinase assembly factor MAT1Homo sapiens (human)2.4
Cyclin-A1Homo sapiens (human)0.047
Cyclin-dependent kinase 3Homo sapiens (human)0.36
Cyclin-dependent kinase 6Homo sapiens (human)0.1775
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.1393
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.1813
Cyclin-YHomo sapiens (human)0.0198

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's4 (50.00)24.3611
2020's3 (37.50)2.80

Authors

AuthorsStudies
Berdini, V; Boulstridge, JA; Carr, MG; Cross, DM; Davis, DJ; Devine, LA; Early, TR; Feltell, RE; Lewis, EJ; McMenamin, RL; Navarro, EF; O'Brien, MA; O'Reilly, M; Reule, M; Saxty, G; Seavers, LC; Smith, DM; Squires, MS; Trewartha, G; Walker, MT; Woodhead, AJ; Woolford, AJ; Wyatt, PG1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Joshi, G; Kalra, S; Kumar, R; Munshi, A1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Kizhake, S; Natarajan, A; Rana, S; Sonawane, YA; Taylor, MA; Zahid, M1
Bian, J; Li, Z; Qin, Z; Tian, Y; Wang, J; Wu, T; Xu, C1
Chen, K; Jiang, H; Li, J; Li, Y; Lin, T; Liu, L; Luo, C; Xu, P; Zhou, B1
Li, J; Liang, C; Liu, C; Qiang, T; Ren, X; Shi, Z; Tian, L; Xing, Y1

Reviews

3 review(s) available for cyc 202 and at 7519

ArticleYear
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
    European journal of medicinal chemistry, 2017, Dec-15, Volume: 142

    Topics: Amino Acid Sequence; Animals; Computer-Aided Design; Crystallography, X-Ray; Cyclin-Dependent Kinases; Drug Design; Humans; Models, Molecular; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Sequence Alignment

2017
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
    Journal of medicinal chemistry, 2020, 11-25, Volume: 63, Issue:22

    Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Cyclin-Dependent Kinase 9; Drug Development; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary

2020
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.
    Journal of medicinal chemistry, 2022, 05-12, Volume: 65, Issue:9

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Female; Humans; Pharmaceutical Preparations; Protein Kinase Inhibitors

2022

Other Studies

5 other study(ies) available for cyc 202 and at 7519

ArticleYear
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.
    Journal of medicinal chemistry, 2008, Aug-28, Volume: 51, Issue:16

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Drug Design; Enzyme Inhibitors; Humans; Mice; Piperidines; Pyrazoles; Structure-Activity Relationship

2008
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.
    Bioorganic & medicinal chemistry letters, 2018, 12-15, Volume: 28, Issue:23-24

    Topics: Amination; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 5; Humans; Molecular Docking Simulation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship

2018
Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
    European journal of medicinal chemistry, 2021, Apr-05, Volume: 215

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Signal Transduction; Structure-Activity Relationship

2021